Matthew D Coates1, Ansh Johri2, Venkata Subhash Gorrepati3, Parth Maheshwari2, Shannon Dalessio3, Vonn Walter4, August Stuart3, Walter Koltun5, Nana Bernasko3, Andrew Tinsley3, Emmanuelle D Williams3, Kofi Clarke3. 1. Department of Medicine, Division of Gastroenterology & Hepatology, Pennsylvania State University College of Medicine, Hershey, PA, USA. mcoates@pennstatehealth.psu.edu. 2. Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USA. 3. Department of Medicine, Division of Gastroenterology & Hepatology, Pennsylvania State University College of Medicine, Hershey, PA, USA. 4. Department of Public Health Sciences and Department of Biochemistry, Pennsylvania State University College of Medicine, Hershey, PA, USA. 5. Department of Surgery, Division of Colorectal Surgery, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Abstract
OBJECTIVES: Inflammation is an important driver of abdominal pain in inflammatory bowel disease (IBD). However, some patients in remission still experience pain. We aimed to identify risk factors associated with abdominal pain in quiescent IBD (QP-IBD) and to characterize differences from patients with active disease experiencing pain (AP-IBD). METHODS: We performed a retrospective analysis utilizing data from our institution's IBD Natural History Registry (January 1, 2015-August 31, 2018). Endoscopic evaluation, concurrent laboratory studies, and validated surveys were completed by participants. Demographic and clinical data were also abstracted. RESULTS: We recruited 122 patients with quiescent disease (65f:57 m; 93CD:26UC:3Indeterminate) for participation in this study, 74 (60.7%) had QP-IBD. QP-IBD patients were more likely to have anxiety/depression (71.6% vs. 25.0%, p < 0.001) or to use antidepressants (47.3% vs. 22.9%, p < 0.010), opiates (18.9% vs. 2.1%, p < 0.010), other pain medications (50.0% vs. 18.8%, p < 0.010), or corticosteroids (18.9% vs. 2.1%, p < 0.010). On logistic regression analysis, corticosteroid use, anxious/depressed state, and female gender were each independently associated with QP-IBD (p < 0.050 or less). Compared with AP-IBD patients (n = 110, 59f:51 m; 69CD:38UC:3Indeterminate), QP-IBD patients were more likely to use antidepressants (45.6% vs. 26.4%, p < 0.010). Platelet, white blood cell, C-reactive protein, and sedimentation rate levels were all less likely to be elevated in QP-IBD (all p < 0.050), though 44% exhibited pathological elevation in at least one. DISCUSSION: QP-IBD was independently associated with corticosteroid use, anxiety/depression, and female gender. Compared with AP-IBD, QP-IBD patients were more likely to use antidepressants and less likely to exhibit elevated inflammatory markers. However, many QP-IBD patients still demonstrated pathological elevation of these tests, demonstrating the need to develop new noninvasive screening methods for this condition.
OBJECTIVES: Inflammation is an important driver of abdominal pain in inflammatory bowel disease (IBD). However, some patients in remission still experience pain. We aimed to identify risk factors associated with abdominal pain in quiescent IBD (QP-IBD) and to characterize differences from patients with active disease experiencing pain (AP-IBD). METHODS: We performed a retrospective analysis utilizing data from our institution's IBD Natural History Registry (January 1, 2015-August 31, 2018). Endoscopic evaluation, concurrent laboratory studies, and validated surveys were completed by participants. Demographic and clinical data were also abstracted. RESULTS: We recruited 122 patients with quiescent disease (65f:57 m; 93CD:26UC:3Indeterminate) for participation in this study, 74 (60.7%) had QP-IBD. QP-IBD patients were more likely to have anxiety/depression (71.6% vs. 25.0%, p < 0.001) or to use antidepressants (47.3% vs. 22.9%, p < 0.010), opiates (18.9% vs. 2.1%, p < 0.010), other pain medications (50.0% vs. 18.8%, p < 0.010), or corticosteroids (18.9% vs. 2.1%, p < 0.010). On logistic regression analysis, corticosteroid use, anxious/depressed state, and female gender were each independently associated with QP-IBD (p < 0.050 or less). Compared with AP-IBD patients (n = 110, 59f:51 m; 69CD:38UC:3Indeterminate), QP-IBD patients were more likely to use antidepressants (45.6% vs. 26.4%, p < 0.010). Platelet, white blood cell, C-reactive protein, and sedimentation rate levels were all less likely to be elevated in QP-IBD (all p < 0.050), though 44% exhibited pathological elevation in at least one. DISCUSSION: QP-IBD was independently associated with corticosteroid use, anxiety/depression, and female gender. Compared with AP-IBD, QP-IBD patients were more likely to use antidepressants and less likely to exhibit elevated inflammatory markers. However, many QP-IBD patients still demonstrated pathological elevation of these tests, demonstrating the need to develop new noninvasive screening methods for this condition.
Authors: M M Walker; N J Talley; M Prabhakar; C J Pennaneac'h; P Aro; J Ronkainen; T Storskrubb; W S Harmsen; A R Zinsmeister; L Agreus Journal: Aliment Pharmacol Ther Date: 2009-01-17 Impact factor: 8.171
Authors: Itta M Minderhoud; Bas Oldenburg; Marguerite E I Schipper; José J M ter Linde; Melvin Samsom Journal: Clin Gastroenterol Hepatol Date: 2007-05-04 Impact factor: 11.382
Authors: Itta M Minderhoud; Bas Oldenburg; Josta A Wismeijer; Gerard P van Berge Henegouwen; André J P M Smout Journal: Dig Dis Sci Date: 2004-03 Impact factor: 3.199
Authors: M Vivinus-Nébot; G Frin-Mathy; H Bzioueche; R Dainese; G Bernard; R Anty; J Filippi; M C Saint-Paul; M K Tulic; V Verhasselt; X Hébuterne; T Piche Journal: Gut Date: 2013-07-22 Impact factor: 23.059
Authors: A A Mikocka-Walus; D A Turnbull; J M Andrews; N T Moulding; G J Holtmann Journal: Aliment Pharmacol Ther Date: 2008-06-03 Impact factor: 8.171
Authors: Calvin J Coffey; Miranda G Kiernan; Shaheel M Sahebally; Awad Jarrar; John P Burke; Patrick A Kiely; Bo Shen; David Waldron; Colin Peirce; Manus Moloney; Maeve Skelly; Paul Tibbitts; Hena Hidayat; Peter N Faul; Vourneen Healy; Peter D O'Leary; Leon G Walsh; Peter Dockery; Ronan P O'Connell; Sean T Martin; Fergus Shanahan; Claudio Fiocchi; Colum P Dunne Journal: J Crohns Colitis Date: 2018-11-09 Impact factor: 9.071
Authors: Jonas Zeitz; Melike Ak; Séverine Müller-Mottet; Sylvie Scharl; Luc Biedermann; Nicolas Fournier; Pascal Frei; Valerie Pittet; Michael Scharl; Michael Fried; Gerhard Rogler; Stephan Vavricka Journal: PLoS One Date: 2016-06-22 Impact factor: 3.240